Psoriasis on the eyelids can be a difficult condition to manage. Learn about the symptoms, complications, and available forms of treatment here.
Uncategorized
AMA, LexisNexis collaborate to enhance network directories
The AMA and LexisNexis Risk Solutions recently announced that they are partnering to create LexisNexis VerifyHCP, which will offer a holistic solution to maintaining up-to-date and accurate network directories of available health care professionals, wh…
Uncategorized
AAO leadership endorses Trump’s nomination of Price
In the wake of President-elect Donald Trump’s nomination of Rep. Tom Price, MD, to lead the U.S. Department of Health and Human Services, the CEO of the American Academy of Ophthalmology urged the U.S. Senate to confirm Price to the position. David W. Parke II, MD, CEO of the American Academy of Ophthalmology, endorsed the nomination by Trump and praised Price as “an excellent choice to serve as secretary of the U.S. Department of Health and Human Services,” in a statement released by the AAO.
The American Refractive Surgery Council is Available to Comment on JAMA Ophthalmology Study
DALLAS–(BUSINESS WIRE)–For the first time, a statistically-valid questionnaire is available to surgeons and researchers for LASIK patients to report and surgeons to scientifically track their experiences with LASIK.
Uncategorized
VIDEO: Sublingual sedation relieves patient anxiety before cataract surgery
At OSN New York, John P. Berdahl, MD, discusses the use of sublingual sedation during cataract surgery, specifically the MKO Melt from Imprimis. The combination of midazolam, ketamine and ondansetron can assist in relieving patient anxiety and decrease…
Uncategorized
Paragon BioTeck receives affirmation of R-phenylephrine hydrochloride formulation in patent case
Paragon BioTeck announced the United States Patent and Trademark Office affirmed claims made by the company in the patent for its R-phenylephrine hydrochloride formulation, which is used to attain dilation of the pupil for ocular examinations. The ruling was handed down by the office after Altaire Pharmaceuticals sought in 2015 to invalidate Paragon’s patent that claims a method of maintaining purity of the formulation. The ruling affirmed that the petition by Altaire was without merit. This is only the fourth written decision by the Patent Trial and Appeals Board, according (Read more...)